[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363583-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-363583-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","development-of-a-multiplex-assay-for-early-detection-of-pancreatic-cancer-in-high-risk-groups","Development of a multiplex assay for early detection of pancreatic cancer in high-risk groups","","Background: Pancreatic cancer is a leading cause of cancer-related death in the United States, with a poor 5-year survival rate largely driven by the difficulty of early detection. Because pancreatic ductal adenocarcinoma (PDAC) is rare, population-wide screening is impractical, motivating a need for improved tests in high-risk groups. Methods: A mass spectrometry-based multiplex plasma assay was built to detect five protein biomarkers and generate a machine-learning composite readout. Results: The assay showed strong discrimination of early-stage PDAC (AUC 0.87; 75% accuracy) and demonstrated PPV >18% and DOR >67 in high-risk cohorts. Conclusions: The straightforward direct-plasma approach enables detection without immunodepletion, enrichment, or prefractionation and outperforms CA19-9.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/development-of-a-multiplex-assay-for-early-detection-of-pancreatic-cancer-in-high-risk-groups/363583/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/development-of-a-multiplex-assay-for-early-detection-of-pancreatic-cancer-in-high-risk-groups/363583.png","ImageObject",300,407,{"name":42,"@type":43},"Elsa","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-14","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"Why is early detection of pancreatic cancer difficult, and why focus on high-risk groups?","Question",{"text":63,"@type":64},"Early detection is challenging, contributing to a low 5-year survival rate. Since PDAC is relatively rare, broad screening is economically and practically unfeasible, so attention shifts to people at high risk to enable earlier, potentially curative intervention.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the multiplex assay detect early-stage PDAC?",{"text":68,"@type":64},"The assay uses mass spectrometry to simultaneously detect five protein biomarkers in whole plasma. Machine learning combines biomarker signals into a composite readout, with a direct sampling approach used to set a reference threshold.",{"name":70,"@type":61,"acceptedAnswer":71},"What performance metrics did the assay achieve in distinguishing early-stage PDAC from controls?",{"text":72,"@type":64},"Receiver operating characteristic analysis yielded an AUC of 0.87 and overall classification accuracy of 75%. In high-risk groups, the assay reported PPV greater than 18% and a diagnostic odds ratio above 67.",{"name":74,"@type":61,"acceptedAnswer":75},"How does this assay compare with the FDA-approved CA19-9 test?",{"text":76,"@type":64},"The document states the multiplex assay significantly outperforms CA19-9 for distinguishing early-stage PDAC from control samples and for detecting PDAC in high-risk populations, with improvements attributed to diverse biological functions represented by the selected biomarkers.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},363583,1790880635,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":33,"preview_urls":150},137455077381,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Pan etal. BMC Cancer (2026) 26:717 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-16058-3](https://doi.org/10.1186/s12885-026-16058-3)  \nRESEARCH Open Access  \nDevelopment of a multiplex assay for early detection of pancreatic cancer in high-risk groups  \nSheng Pan 1,2*, Ramesh Karki 1, Lisa A Lai3, Chad J Creighton4,5, Teresa A Brentnall3, Randall E Brand6 and Ru Chen7*  \nAbstract  \nBackground Pancreatic cancer ranks as the third leading cause of cancer-related deaths in the United States, with a dismal 5-year survival rate of only 13% . This poor prognosis is largely due to the challenge of early detection, which is crucial for effective treatment. Given the low prevalence of pancreatic ductal adenocarcinoma (PDAC), widespread screening is impractical and economically unfeasible. We present a novel, multiplex blood-based assay aimed to improve early detection for PDAC in high-risk populations.  \nMethods Utilizing comprehensive proteomic data, we established a mass spectrometry-based assay that simultaneously detects a panel of five protein biomarkers (APOA4, SERPING1, LRG1, C3, ORM1) in whole plasma. Machine learning was applied to construct a composite biomarker readout, and a “direct sampling” approach was employed to establish a reference threshold for PDAC detection. Characterized through Receiver Operating Characteristic (ROC) analysis with case-control cohorts from multiple medical centers, the assay’s efficacy was further evaluated in high-risk groups.  \nResults The assay achieved an area under the curve (AUC) of 0.87 and an overall classification accuracy of 75% in distinguishing early-stage PDAC cases from controls. Its efficacy was further assessed in high-risk groups, including adults aged 50 and older with new-onset diabetes, individuals with familial risks, and patients with chronic pancreatitis. Across all high-risk groups, the assay demonstrated a positive predictive value (PPV) exceeding 18% anda diagnostic odds ratio (DOR) above 67-sufficient to identify potential PDAC cases for further clinical evaluation. Conclusions This straightforward multiplex assay enables direct detection of early-stage PDAC from whole plasma without the need for immunodepletion, enrichment, or prefractionation, demonstrating high efficacy and strong clinical applicability. It significantly outperforms the FDA-approved CA19-9 in distinguishing early-stage PDAC from control samples and in detecting PDAC among high-risk populations. The improved performance is attributable to the diverse biological functions and pathways represented by the selected biomarkers, which are actively involved in PDAC development. Although the assay is not predictive in nature, its diagnostic strength stems from the functional  \n*Correspondence: Sheng Pan [sheng.pan@uth.tmc.edu](sheng.pan@uth.tmc.edu)[ ](sheng.pan@uth.tmc.edu)Ru Chen [ru.chen@bcm.edu](ru.chen@bcm.edu)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons","cbCaiazYmsXK3Hqf","https://ap.wps.com/l/cbCaiazYmsXK3Hqf","pdf",3040716,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Keywords\n# Background\n## Rationale for early detection and high-risk screening\n## Limitations of CA19-9 and the need for new biomarkers","[{\"question\":\"Why is early detection of pancreatic cancer difficult, and why focus on high-risk groups?\",\"answer\":\"Early detection is challenging, contributing to a low 5-year survival rate. Since PDAC is relatively rare, broad screening is economically and practically unfeasible, so attention shifts to people at high risk to enable earlier, potentially curative intervention.\"},{\"question\":\"How does the multiplex assay detect early-stage PDAC?\",\"answer\":\"The assay uses mass spectrometry to simultaneously detect five protein biomarkers in whole plasma. Machine learning combines biomarker signals into a composite readout, with a direct sampling approach used to set a reference threshold.\"},{\"question\":\"What performance metrics did the assay achieve in distinguishing early-stage PDAC from controls?\",\"answer\":\"Receiver operating characteristic analysis yielded an AUC of 0.87 and overall classification accuracy of 75%. In high-risk groups, the assay reported PPV greater than 18% and a diagnostic odds ratio above 67.\"},{\"question\":\"How does this assay compare with the FDA-approved CA19-9 test?\",\"answer\":\"The document states the multiplex assay significantly outperforms CA19-9 for distinguishing early-stage PDAC from control samples and for detecting PDAC in high-risk populations, with improvements attributed to diverse biological functions represented by the selected biomarkers.\"}]","Development of a multiplex assay for early detection of pancreatic cancer in high-risk groups | PDF",1790151944,33,[151,155,159,163],{"page_no":22,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/76b2b8ea4ef4cd949afdd4370f111486.webp",983,1310,{"page_no":26,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0f23b94572342faeebacf4a5a2f7674f.webp",982,1309,{"page_no":30,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4b7f67ce8268ed3b43f94524e918593b.webp",981,1308,{"page_no":33,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0501a768e71d59989ef4810000b8ae05.webp",980,1306]